

REPORT OF THE ELEVENTH
WHOPES
WORKING GROUP MEETING

REPORT OF THE ELEVENTH **WHOPES** WORKING GROUP MEETING

WHO/HQ, GENEVA
10—13 DECEMBER 2007

Review of:
SPINOSAD 7,48% DT
NETPROTECT®
DURANET®
DAWAPLUS®
ICON® MAXX



World Health
Organization

REPORT OF THE ELEVENTH WHOPES WORKING GROUP MEETING

**WHO/HQ, GENEVA
10–13 DECEMBER 2007**

REVIEW OF:

**SPINOSAD 7.48% DT
NETPROTECT®
DURANET®
DAWAPLUS®
ICON® MAXX**



**CONTROL OF NEGLECTED TROPICAL DISEASES
WHO PESTICIDE EVALUATION SCHEME**

© World Health Organization 2008

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication does not necessarily represent the decisions or the stated policy of the World Health Organization.

CONTENTS

	Page
1. INTRODUCTION	1
2. REVIEW OF SPINOSAD 7.48% DT	2
2.1 Efficacy – background and supporting documents	3
2.2 Efficacy – WHOPES supervised trials	4
2.3 Conclusions and recommendations	7
3. REVIEW OF NETPROTECT®	9
3.1 Safety assessment	9
3.2 Efficacy – WHOPES supervised trials	11
3.2.1 Laboratory studies	11
3.2.2 Experimental hut studies	13
3.3 Conclusions and recommendations	19
4. REVIEW OF DURANET®	21
4.1 Safety assessment	21
4.2 Efficacy – WHOPES supervised trials	22
4.2.1 Laboratory studies	22
4.2.2 Experimental hut studies	23
4.3 Conclusions and recommendations	27
5. REVIEW OF DAWAPLUS®	29
5.1 Safety assessment	29
5.2 Efficacy – background and supporting documents	30
5.2.1 Laboratory studies	30
5.2.2 Field studies	32
5.3 Efficacy – WHOPES supervised trials	37
5.3.1 Laboratory studies	37
5.3.2 Experimental hut studies	38
5.4 Conclusions and recommendations	42
6. REVIEW OF ICON® MAXX	44
6.1 Safety assessment	44
6.2 Efficacy – background and supporting documents	46

6.3	Efficacy – WHOPES supervised trials	50
6.3.1	Laboratory studies	50
6.3.2	Experimental hut studies	52
6.4	Conclusions and recommendations	54
7.	REVIEW OF WHOPES LABORATORY AND SMALL-SCALE FIELD TESTING, EVALUATION OF LONG-LASTING INSECTICIDAL MOSQUITO NETS AND THE WAY FORWARD	57
ANNEX 1:	CHARACTERIZING THE ACTIVE INGREDIENT RELEASE CHARACTERISTICS OF LONG-LASTING INSECTICIDAL MOSQUITO NETS SUBJECTED TO REPEATED WASHING	61
Annex 2:	LIST OF PARTICIPANTS	99
Annex 3:	REFERENCES	101

1. INTRODUCTION

The eleventh meeting of the WHOPES Working Group, an advisory group to the WHO Pesticide Evaluation Scheme (WHOPES), was convened at WHO headquarters in Geneva, Switzerland, from 10 to 13 December 2007. The objective of the meeting was to review the reports of testing and evaluation of spinosad 7.48% DT (tablet for direct application) of Dow AgroSciences, France, for mosquito larviciding, and three long-lasting insecticidal mosquito nets (LNs) for malaria prevention and control, namely: (i) Netprotect[®], deltamethrin (incorporated into filaments) LN of Intelligent Insect Control, France; (ii) DuraNet[®], alpha-cypermethrin (incorporated into filaments) LN of Clarke Mosquito Control, USA; and (iii) DawaPlus[®], deltamethrin (coated) LN of Tana Netting, Thailand. The objective also included the review of reports of Icon[®] MAXX (an insecticide treatment kit) of Syngenta, Switzerland, for treatment of mosquito nets for malaria prevention and control.

The meeting was attended by 15 scientists (see Annex 1: List of participants). Dr Marc Coosemans was appointed as Chairman and Dr Purushothaman Jambulingam as Rapporteur. The meeting was convened in plenary and group sessions, in which the reports of the WHOPES supervised trials and relevant published literature and unpublished reports were reviewed and discussed (see Annex 2: References). Recommendations on the use of the above-mentioned products were made.

The meeting also reviewed the results of WHOPES testing and evaluation of LNs to identify the information on and data gaps for future development and evaluation of such products, and made recommendations for further action.

2. REVIEW OF SPINOSAD 7.48% DT

Spinosad is a natural product produced by fermentation technology that employs the bacterium *Saccharopolyspora spinosa* (Actinomycetales) from which it is obtained by extraction and purification of the whole broth. Spinosad 0.5% GR and 12% SC have previously been evaluated by WHOPES for mosquito larviciding. A WHO safety assessment of spinosad and recommendations¹ for its use, as well as WHO specifications² for quality control of the named products, have previously been published. The WHO Programme on Chemical Safety considers spinosad to be a mosquito larvicide that poses no undue threat to the health of users or to the environment. However, it notes that this assessment relates to spinosad, with the equivalent impurity profile of that used for development of WHO specifications.

Spinosad DT is a tablet for direct application for control of container-breeding mosquitoes. Each tablet weighs approximately 1.34 g and is 12 mm in diameter. The nominal content of the active ingredient is 75 g/kg, equal to approximately 100 mg of active ingredient (AI) per tablet. Each tablet is intended for application to 200 L of water per container for mosquito larval control, i.e. 0.5 mg/L AI.

Each tablet consists of two homogenous horizontal layers of technical spinosad: an outer layer consisting of technical spinosad in an effervescent system providing fast release of the active ingredient upon application to water; and an inner layer formulated to dissolve in water gradually over time.

¹ *Report of the tenth WHOPES Working Group Meeting, WHO/HQ, Geneva, 11–14 December 2006.* Geneva, World Health Organization, 2006 (WHO/CDS/NTD/WHOPES/2007.1; available at <http://www.who.int/whopes/recommendations/wgm/en/>).

² <http://www.who.int/whopes/quality/newspecif/en/>.

The following are extracts from the material safety data sheet of the manufacturer for spinosad 7.48% DT.

Acute oral LD ₅₀ (rat)	>5000 mg/kg
Acute inhalation LC ₅₀ (rat)	Vapours are unlikely owing to physical properties. Single exposure to any trace dust is not likely to be hazardous
Acute dermal LD ₅₀ (rat)	>5000 mg/kg
Skin irritation (rabbit)	Essentially non-irritating to skin
Eye irritation	May cause slight transient (temporary) eye irritation
Sensitization (guinea-pig)	No allergic reaction

The current review assesses the efficacy of spinosad DT against container-breeding mosquitoes in comparison with the GR formulation for which WHO recommendations have previously been published.

2.1 Efficacy – background and supporting documents

Martinique, France

Marcombe et al (2007) carried out a simulated field trial to evaluate, in plastic containers (175-L capacity), the residual efficacy of spinosad 7.48% DT, in comparison with spinosad 0.5% GR formulation against *Aedes aegypti* in Fort de France, Martinique (French West Indies). Efficacy and persistence were compared over a period of 60 days in blue plastic containers filled with 145-L of domestic water and covered with a mosquito net to prevent oviposition by wild mosquitoes and deposits of debris. The containers were placed under a shelter to protect them from direct sunshine and from rain. The GR formulation was used at a dosage of 0.1 mg/L and 0.5 mg/L; the DT formulation was used at 0.67mg/L AI (1 tablet/145 L). Each dosage was tested with three replicates and three control (untreated) jars.

A total of 100 third-instar larvae of the F1 generation of field-

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29466